SLFN11 and Ewing sarcoma: SLFN11 has been recognized as a biomarker predictive of response to various DNA-damaging agents and PARPi across multiple cancer types, including gastric cancer (4), esophageal cancer (5), small cell lung cancer (6–9), breast cancer (10), ovarian cancer (11, 12), prostate cancer (13), Ewing sarcoma (14), glioblastoma (15), head and neck cancer (16), colorectal cancer (17, 18), clear cell renal cell carcinoma (19) and hepatocellular carcinoma (20).